The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the LiFraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T4C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.
Introduction
The checkpoint kinase CHK2 (hcds1, chk2, the protein coded for by the CHEK2 gene) plays an important role in regulation of cell cycle checkpoints and programmed cell death in response to DNA damage, particularly to DNA double-strand breaks . Activated either through phosphorylation by the upstream kinase Ataxia Telangiectasia Mutated (ATM) (Matsuoka et al., 1998) or independently of ATM (Theard et al., 2001) , CHK2 undergoes oligomerization and auto-phosphorylation (Lee and Chung, 2001; Ahn et al., 2002; Xu et al., 2002) . Thereafter, CHK2 spreads the damage signal by phosphorylating multiple substrates including the Cdc25A (Falck et al., 2001b) and Cdc25C (Matsuoka et al., 1998) phosphatases, BRCA1 (Lee et al., 2000) , and p53 (Tominaga et al., 1999; Caspari, 2000) , thereby triggering different pathways involved in growth arrest or apoptosis .
The finding that CHK2 regulates the p53 tumour suppressor through phosphorylation of the p53 protein at Ser20, Thr18, and likely also other residues (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) has been of particular interest to oncogenesis. Such CHK2-mediated phosphorylation inhibits the interaction of p53 with Mdm2, the proto-oncogenic ubiquitin ligase that negatively regulates p53, and facilitates the interaction of p53 with its transcriptional co-activator p300 (Craig et al., 2003) . This emerging concept of CHK2 as an upstream positive regulator of p53 has been further strengthened by genetic and functional data demonstrating that deletion of CHEK2 in mice, or interference with CHK2 function in live human cells, undermine the DNA damage-induced transcriptional activation of p53 in vivo (Hirao et al., 2002; Takai et al., 2002; Lukas et al., 2003) .
Another genetic link between p53 and CHK2, and the first indication that CHK2 itself is a tumour suppressor, came from the identification of germline mutations in the CHEK2 gene in some families with the Li-Fraumeni (LFS) syndrome, a cancer prone condition attributable in many cases to germline mutations of the TP53 gene (Bell et al., 1999; Frebourg et al., 2001; Wu et al., 2001) . More recent studies have implicated certain genetic variants of CHEK2 as alleles predisposing to carcinomas of the breast, colon, and prostate (Meijers-Heijboer et al., 2002; Sodha et al., 2002a; Vahteristo et al., 2002; Dong et al., 2003; Meijers-Heijboer et al., 2003) , and somatic mutations of CHEK2 have been identified in a broad range of human tumour types .
Despite these recent advances in understanding the biology and pathology of CHK2, a number of issues related to the role of CHK2 in oncogenesis in general, and its functional link with p53 in particular, remain to be elucidated. For example, while the functional impact of some of the CHK2 variants and mutants has been clarified, including loss of kinase activity, protein destabilization, and impaired recognition of the substrates Falck et al., 2001a, b; Matsuoka et al., 2001; Wu et al., 2001) , the biological significance of many cancer-associated CHK2 alterations remains unknown. Also, whereas there is little doubt that CHK2 regulates p53 function, this issue is complicated by the fact that there are numerous and partly redundant ways to control p53. Furthermore, unlike the mutually exclusive mutations of CHEK2 and TP53 among the Li-Fraumeni families, concomitant aberrations of both genes occur in some tumours (Bell et al., 1999; Falck et al., 2001a; Reddy et al., 2002; Sullivan et al., 2002) , likely reflecting the engagement of p53 and CHK2 in multiple pathways . To help elucidate these important issues, we have undertaken a combined genetic and functional protein analysis of CHK2 in a series of advanced breast carcinomas previously characterized for their TP53 status. Our results, including the identification of a novel mutation that leads to so-far unprecedented neutralization of CHK2 via its cytoplasmic sequestration, and an unexpected phenomenon of a very complex repertoire of splicing variants of CHK2, are presented in this report.
Results
Mutational analysis of CHEK2 in breast cancer tissue samples cDNA generated from 60 biopsies (53 primary tumour samples, four normal breast tissue samples and three skin samples) obtained from 53 patients were analysed by PCR and DNA sequencing for possible CHEK2 mutations. One novel CHEK2 mutation, 1368insA, was identified in the tumour tissue from one of the patients (Figure 1a and b) . This mutation generates a novel stop codon in the 5 0 -end of exon 13, leading to truncation of CHK2. Two previously described variants: the silent polymorphism 252A4G and the 470T4C substitutions were detected in one tumour each (Figure 1a) . The 470T4C substitution results in an exchange of isoleucine with threonine (I157T), a variant previously linked to cancer (Allinen et al., 2001; Wu et al., 2001) .
The observed mutations were verified by amplification and sequencing of genomic DNA. Analysis of lymphocytic genomic DNA from the patients harbouring mutant CHEK2 identified the 252A4G polymorphism, but not the 1368insA or the 470T4C variants, confirming the latter two as somatic mutations. Tumour samples harbouring CHEK2 mutations always harboured some wild-type CHEK2 and, in addition, they were wild type for TP53. Interestingly, the tumour harbouring the 1368insA mutation revealed lack of sensitivity to doxorubicin therapy. Given that the mutated CHEK2 transcript was expressed in excess of the wild type in all samples, it is likely that the wild-type transcript originated from contaminating normal tissue. This interpretation, consistent with likely loss of the wild-type allele in the tumour, is further supported by the analysis of CHK2 protein (see below).
Functional analysis of the 1368insA mutant of CHK2
To assess the potential functional defect of the newly identified 1368insA mutation, the mutant sequence was cloned into a mammalian expression vector and analysed in a series of assays. Such expression studies revealed that the 1368insA protein has approximately the same stability as wild-type CHK2 and is not labile as the previously described 1100delC variant associated with familial breast cancer (Figure 2a ). However, in contrast to the wild-type CHK2, the mutant 1368insA protein localizes exclusively to the cytoplasm of human cells, as seen in immunofluorescence analysis of transfected cell lines (Figure 2b ). This suggests the 1368insA mutant to be nonfunctional, as the main substrates for CHK2 phosphorylation are located in the nucleus.
Immunohistochemical analysis of CHK2 protein
We have previously raised and characterized monoclonal antibodies to CHK2 ) and demonstrated their usefulness in detecting some types of CHK2 alterations, particularly those that grossly Vahteristo et al., 2002) . Here, we employed this approach to assess the abundance and subcellular localization of CHK2 in a blind manner, using archival paraffin sections from 35 tumours, a major subset of the 53 cases studied genetically (see above) and collected from a previously characterized study (Geisler et al., 2001) . To ensure reproducibility, we used independently two mouse monoclonal antibodies recognising distinct epitopes within the FHA and SQ-rich domains of CHK2, respectively , and with both reagents we obtained virtually identical results. Normal cells present in the sections served as internal controls, showing strong and almost homogeneous nuclear staining for CHK2 (Figure 2c , upper left panel). Interestingly, three distinct patterns of CHK2 staining were seen among the tumour samples, examples of which are shown in Figure 2c (top right and the two bottom panels). First, the majority of the tumours showed nuclear staining for CHK2 analogous to normal tissue ( Figure 2c , upper right panel). Second, seven tumours showed various degrees of reduction or loss of CHK2 while the remaining signal, when present, was still nuclear (Figure 2c , lower left panel). One of these seven patients had a loss of 80% CHK2 expression in the tumour area. Third, a surprising, previously unreported cytoplasmic staining for CHK2 was found in one of the tumours (Figure 2c , lower right panel). Upon decoding the samples, the latter tumour was identified as the one harbouring the 1368InsA mutation, while none of the seven cases with reduced CHK2 levels harboured CHEK2 mutations. Thus, consistent with the in vitro expression studies (Figure 2a, b) , the cytoplasmic mislocalization of the mutant 1368InsA CHK2 protein was obvious also in the original biopsy specimen from the patient.
Reduced CHK2 levels did not correlate to the presence of specific splice-variants, or groups of splicevariants. However, as quantitative studies on tumor biopsies were not feasible, the possibility of increased transcription of unstable mRNA transcripts in these tumours may not be excluded.
CHEK2 RNA splice-variants
As CHEK2 has several known pseudogenes, the CHEK2-analysis were performed using cDNA as template. The pseudogenes are homologous to exons 10-14 of CHEK2 (Sodha et al., 2002b) ; thus our sense cDNA primers, located in CHEK2 exon1, will not bind these sequences. The CHEK2 PCR product contained several DNA bands in addition to the expected 1640 bps wild-type chk2-specific band (Figure 3 ). Cloning and sequencing of the first round of PCR revealed amplification of two fragments unrelated to CHEK2 (400 and 1200 bps respectively, Figure 3a) , and nested PCR was therefore employed. Cloning and sequencing of the nested PCR products identified all fragments, including those isolated from normal tissues, as splice-variants of CHEK2 mRNA (Figure 3b) . None of the fragments corresponded to known genomic sequences. To assess the occurrence of mRNA splice-variants in the tumours from each patient, at least 15 clones were sequenced so that all bands in the original CHEK2-PCR were accounted for.
We found alternatively spliced CHEK2 together with wild-type CHEK2 in all tumours, but also in all the normal tissue samples examined. There is a tendency of tumour samples to exhibit more complex CHEK2 splicing than normal samples, and the breast cancer cell lines examined in parallel showed even higher complexity of splicing than the biopsy tumour samples (average of 10 splice-variants per cell-line, six per tumour sample and four per normal tissue sample). Tumour samples harbouring a TP53-mutation had the same average number (n ¼ 6) of CHEK2 splice variants as tumour samples wild type for TP53. While the type and number of different RNA splicevariants vary substantially between individual samples, some splice variants are seen in most of the cancer biopsies.
In total, we observed about 90 different splice variants of CHEK2 RNA; of these, about 50% were detected in at least two different tumours. Interestingly, tumours harbouring CHEK2 variants generated through combination of splices almost always harboured additional CHEK2 variants containing the single splice form. For instance, tumours harbouring CHEK2 mRNA lacking exons 7 and 9 in concert in general also harboured CHEK2 lacking only either exon 7 or exon 9. The frequency of a combination of splices is usually roughly equal to the product of the frequencies of observation of the individual splicing events. However, certain splice events have a tendency to appear concomitantly. Thus, considering all splice variants lacking exon 4, loss of exon 4 alone is observed in 38% of the sequenced CHEK2-fragments, loss of both exons 4 and 7 together occurs in 36%, while loss of exons 4 and 9 only occur in 7%; despite the fact that loss of exon 9 and exon 7 in general occur by the same incidence ( Figure 4) .
In total, 50% of the splice variants were spliced outside the normal exon-intron boundaries of wild-type CHEK2. Some variants contain intron sequences, which on genomic sequence inspection may be exons that are not included in wild-type CHEK2 ( Figure 5 ). One of these sequences, exon Y (the CHEK2-Sub3 variant, Figure 5 ), is always substituted for exon 3, while the other alternative exons, X and Z, are inserted as additional sequences into the wild-type mRNA. The most frequent splicing event is the loss of complete exons. A defined group of alternative splice variants of CHEK2 are those where splicing occurs within the wildtype exon sequences, often leading to loss of large parts of wt CHEK2 mRNA. Intraexon splicing events resulting from the use of non-normal splice donor or acceptor sites, and almost never occur together with other splices.
To ensure that the observed RNA splice variants were not PCR-artefacts, RPA was carried out on a selection of RNA isolates from cell lines using splice-specific probes (Table 1) . While different cell lines harboured several splice variants, wild-type mRNA was always in excess (results not shown).
Analysis of CHEK2 alternative splicing by semiquantitative PCR
Some splice variants were considered of particular interest, as they were observed among patients not responding to primary doxorubicin therapy (Geisler et al., 2001) . Thus, two commonly occurring (del2-3 and insX) and two rare (del2-12 and insZ) splice variants were subjected to semiquantitative PCR in patients of interest. Both common splice variants and the del2-12 were present at much lower levels than wild-type CHEK2, and in approximately equal amounts in all patients tested. Interestingly, the rare insZ variant was significantly increased in one of the patients, and in addition it seemed to be present in higher amounts than wild-type CHEK2 (Figure 6 ). In the results from the first round of PCR full-length wt CHEK2 is seen in some samples, two recurring unspecific bands of sizes B400 and B1200 bps are seen in some samples, and traces of CHEK2 splice-variants constitutes the remaining bands. (b) After a second round of PCR the unspecific bands are gone and wt CHEK2 is seen in all samples. All other bands (marked by stars) are splice-variants of CHEK2 (verified by purification from gel followed by sequencing) Figure 4 Multiple-splicing dependencies. Considering all sequenced CHEK2-fragments that include loss of exon 4, 38% of fragments lack only exon 4, 36% lack exons 4 and 7, and 7% of fragments lack exons 4 and 9. The remaining 19% of the fragments lack exon 4 together with other exons. Loss of exons 4 and 7 are significantly more frequent than loss of exons 4 and 9, even though loss of exon 7 and 9 are seen at comparable frequencies, all CHEK2-fragments counted CHEK2 alterations in breast cancer V Staalesen et al
Functional testing of CHEK2 splice variants
The most frequently occurring CHEK2 splice variants, together with a selection of CHEK2 mRNA variants encoding major deletions or insertions ( Figure 5 , Table 2a ), were cloned into expression vectors and tested for kinase activity and subcellular localization. In vitro kinase activity was measured as incorporation of radioactively labelled phosphate in p53 and CHK2 upon CHK2 stimulation (Figure 7 ). All variants, except isoC, which is located pan-cellularly, localize to the nucleus (Table 2b) . Only the del2-3 variant partly preserved the Chk2 5-strt-as B600 SacI (180), ApaI (290) Figure 6 Semiquantitative PCR results. Circles denote wt-bands, and stars splice-specific bands. Well 1-4 are the del2-12, del2-3, insZ and insX variants respectively. One patient (a) displayed increased amounts of the insZ splice-variant (well 3) as compared to all other patients (e.g. b). The other splice-variants seem to be present at low levels compared to wt-CHEK2 mRNA and with no variation between patients. Representative results from repeated experiments are shown (Table 2b ) expressed minimal activity.
Discussion
We believe the data presented in this study can contribute to the rapidly expanding knowledge about the role of CHK2 in tumorigenesis in at least three aspects: (i) by identification and characterization of the CHK2 mutants including the novel mutation 1368insA that subverts the CHK2 function through a mechanism distinct from all previously reported CHK2 mutants; (ii) by the finding of a previously unsuspected phenomenon of complex splicing of CHEK2 and partial characterization of the splice variants; and (iii) by additional insights into the CHK2-p53 link and the emerging significance of this tumour suppressor pathway in human cancer. In our series of 53 cases of stage III breast carcinomas, we identified one patient with the previously reported polymorphism 252A4G (Bell et al., 1999; Zheng et al., 2001; Reddy et al., 2002) , and two CHK2 mutations, 470T4C (Bell et al., 1999; Allinen et al., 2001 ) and the truncating mutation 1368insA, each observed in one patient. The 470T4C (I157T) variant was first observed among the Li-Fraumeni families (Bell et al., 1999) and later suggested to be a rare polymorphism, based on population incidence in healthy individuals (Allinen et al., 2001) . However, functional studies of the corresponding mutant protein (I157T) altered in the FHA domain revealed its grossly impaired ability to bind downstream substrates, including Cdc25A (Falck et al., 2001b) and p53 (Falck et al., 2001a) . Furthermore, most recent large-scale population genetic studies in Finland concluded that the 470T4C (I157T) variant predisposes to higher incidence of carcinomas of the prostate (Seppa¨la¨et al., 2003) and breast (Kilpivaara et al., 2004) . Finally, given that the CHK2-I157T protein is stable and capable of dimerizing with the wild-type protein (Kilpivaara et al., 2004) , and that it interferes with the endogenous wild-type CHK2 in vivo (Falck et al., 2001b) , it is plausible that this variant of CHK2 contributes to oncogenesis through a dominantnegative effect.
Arguably, the most significant result of our mutation analysis is the identification of one novel mutation, 1368insA, which lead to frameshift and missense translation of exon 12, causing truncation of CHK2 at the start of exon 13. Transfection experiments revealed that this mutant protein is stable yet aberrantly located to the cytoplasm, leaving it inaccessible for activation by ATM as well as sequestered from its known downstream targets all of which localize mainly if not exclusively to the nucleus . The lack of nuclear CHK2 seen by immunohistochemical staining of tumour cells of the patient presenting the 1368insA mutation indicates wild-type CHK2 to be absent or expressed at very low levels in this tumour. We propose that the 1368insA represents the first example of a new class of cancer-associated loss-of-function mutants of CHK2, operating through subcellular mislocalization.
The second major result of the present study is the discovery of the complex alternative splicing of CHEK2, a phenomenon not reported previously. The only available indication of potential alternative splicing of CHEK2 are two variants listed in the NCBI sequence databases: NCBI Acc. Nr: AB040105, deletion of CHEK2 exon 9 (del9), and Acc. Nr: AF217975, insertion of 114bp between CHEK2 exons 3 and 4 (insZ). One reason why this phenomenon has not been detected previously could be that common methods for Ins X has inserted 129 bps of intron 1 between exons 1 and 2. c InsZ has inserted 114 bps of intron 3 between exons 3 and 4, the insert contains an in-frame stop codon Although our study does not allow any firm conclusions about the potential significance of the numerous splice variants of CHK2 in tumorigenesis, we do show by functional analysis that the tested variants may display aberrant function or localization, and that at least some, exemplified by the insZ variant here, may be expressed at significantly high levels in the tumours. Thus, the insZ variant was significantly increased in one patient with a progressive disease after treatment ( Figure 6 ). This variant has a 114 bp fragment of intron 3 inserted between exons 3 and 4. This insertion encodes 36 amino-acid residues before a termination codon, and the variant contains only the SQ/TQ and FHAdomains. This variant might conceivably bind wild-type CHK2 during activation and, lacking kinase activity, might act in a dominant-negative manner.
Alternative splicing has been suggested as a mechanism to control gene activity by generating transcripts encoding proteins with different activities from the same gene, and aberrant splicing of some genes, such as Mdm2, has been detected in cancers (Sigalas et al., 1996) . Later results have indicated a more complex pattern of Mdm2 splicing than originally reported in malignant but also in normal tissue (Kraus et al., 1999; Hori et al., 2000; Evdokiou et al., 2001; Bartel et al., 2004) . Furthermore, the expression and functional importance of variant isoforms of p53 and p73 has also been reported (Ishimoto et al., 2002; Maier et al., 2004) , with particular high expression of the oncogenic delta-N truncated form of p73 in vulvar cancer (O'Nions et al., 2001; Ishimoto et al., 2002) . Although still largely speculative in the case of CHK2, we hope that our work on the CHEK2 splice variants in breast cancer may provide a solid basis for an analogous challenging line of research in the future.
Finally, our data also provide some new information related to the currently debated link between the CHK2 and p53 tumour suppressors and its significance in responses to genotoxic stress and molecular pathogenesis of human cancer . In our series of tumours, mutations of TP53 and CHEK2 occurred in mutually exclusive subsets of cases, as p53 was wild-type in tumours with the I157T and 1368insA mutations of CHK2, and vice versa, all the carcinomas previously found to harbour mutant TP53 (Geisler et al., 2001) appear to express wild-type CHK2. On the other hand, it is clear from the study by Sullivan et al. (2002) that mutations of both CHEK2 and TP53 can occur in the same breast tumour, and we are currently initiating larger studies to determine whether such mutations are more likely to occur in the same or alternative subsets of tumours, and in the former scenario what may be the order of such events during the course of tumour development.
To clarify these issues should not only help to better understand the biology of the CHK2-p53 pathway, but possibly assist in better management of the disease in the future. For instance, among the few cases of breast carcinomas within our series that were resistant to doxorubicin therapy, several tumours harboured mutant TP53 (Geisler et al., 2001) . Interestingly, the tumour identified here as deficient in CHK2 due to the novel 1368insA mutation (apparently accompanied by the loss of the second allele), showed a very similar phenotype of resistance to doxorubicin, despite its wild-type TP53. As CHK2 becomes activated in response to doxorubicin (our unpublished data) and the pathway(s) regulated by CHK2 and/or p53 have proapoptotic effects Zhou and Bartek, 2004) , it is plausible to speculate that mutations of these genes may be causally linked with the resistance to chemotherapy or radiotherapy in some tumours (Lnning, 2003 (Lnning, , 2004 . This notion is supported by the dominant phenotype of CHK2-deficient mice, whose various tissues are more resistant to ionizing radiation compared to wild-type animals (Hirao et al., 2002; Takai et al., 2002) . Thus, understanding the function(s) of the CHK2-p53 axis and its relevance for prediction of therapeutic responses may have clinical implications. This issue may become particularly relevant if the emerging concepts of using selective inhibitors or activators of the DNA damage checkpoint components such as CHK2 for chemosensitization or chemoprotection (Zhou and Bartek, 2004) should materialize.
Materials and methods

Patients
A total of 53 tumour samples were examined. Out of these, 36 (Geisler et al., 2001) and nine (Geisler et al., 2003) were drawn from prospective studies evaluating the predictive value of TP53 status with respect to chemosensitivity. In addition, one metastatic deposit and seven additional primary tumours were included. Normal breast samples were included from four and skin tissue samples from three of the latter seven. The studies were approved by the Regional Ethical Committee, and the patients gave their written informed consent.
Tissue and cell lines
All tissue samples were frozen in liquid nitrogen in the operating theatre as previously described (Geisler et al., 2001) . From 35 of the tumours, also formalin-fixed, paraffinembedded material was available for the immunohistochemical analysis performed in this study (see below). For in vitro testing, we used the breast cancer cell lines HCC1569, 
RNA purification and cDNA synthesis
Total RNA was purified from cell lines or tissue biopsies by Trizol (Life Technologies) extraction. mRNA was reverse transcribed by Superscript II reverse transcriptase (Life Technologies) using random dpN hexamers and oligodpT 16 as primers.
Genomic DNA purification
For those patients expressing a potential mutation or polymorphism based on analysis of the tumour sample, genomic DNA was analysed to confirm the alterations. Genomic DNA was purified from tumour tissue and lymphocytes by QIAamp DNA Mini Kit (Quiagen) according to the manufacturer's instructions.
CHEK2 PCR and sequence analysis
CHEK2 was amplified from cDNA by nested PCR using the following primers: chk2-s1 and chk2-as1 for the first PCR; and chk2-s3 and chk2-as2 for the second PCR (all primers described in Table 3 ). The program were as follows for both reactions: 941C for 5 min, followed by 35 cycles of 941C for 1 min, 581C for 1 min and 721C for 2 min, before a final step of 721C for 7 min.
The PCR-products were cloned into the pCR TOPO 2.1 vector (Invitrogen). A minimum of 15 plasmids from each cell line/patient were sequenced until at least 10 different sequences covered all parts of the CHEK2 coding sequence. Mutations were verified by repeating, in independent experiments, all steps from cDNA synthesis through sequencing, and by PCRamplification and sequencing of the relevant genomic segments.
DNA sequencing was carried out directly on 1 ıl of the plasmids using Big Dye terminator mix (Applied Biosystems), with both primers chk2-s3 and chk2-as2. After an initial 5 min denaturation at 941C, the sequencing reaction was carried out for 25 cycles of 10 s at 941C, followed by 5 s at 551C and 4 min at 601C. Capillary gel electrophoresis, data collection and sequence analysis were performed on an automated DNA sequencer (ABI 3700, Perkin-Elmer Biosystems).
Genomic CHEK2 PCR
Genomic PCR was performed using the primers described in Hofmann et al. (2001) . Due to possible amplification of CHEK2 pseudogenes (Sodha et al., 2000) along with the CHEK2-gene, the PCR products were cloned into the pCR TOPO 2.1 vector (Invitrogen) followed by plasmid purification by standard alkaline lysis miniprep (Qiagen kit). Plasmids were sequenced until at least 10 correct CHEK2 sequences had been covered.
Subcloning of alternatively spliced CHEK2 mRNA variants
Fragments of CHEK2 mRNA splice-variants were generated as follows: Appropriate primers were selected and the PCR program was the same as for the nested CHEK2 PCR with plasmids containing the relevant splice-variants as template. The PCR products were cloned into the pCR TOPO 2.1 vector. Insert lengths were verified by PCR and insert orientation was checked by restriction enzymes. Primers and restriction enzymes for the relevant splice-variants are listed in Table 1 .
RNAse protection assay (RPA) of alternatively spliced CHEK2 RNA RNA probes were constructed to detect the most frequent occurring of CHEK2 splice-variants (Table 1 ). The templates for probe synthesis were based on the pCR TOPO 2.1 vector, which contains a T7 RNA polymerase promoter region, with inserted CHEK2 cDNA. A region spanning the insert and the T7 promoter region of plasmids with the correct CHEK2 inserts in the correct orientation (see above and Table 1) were amplified by PCR, and the product purified from a 2% LMP agarose gel after 1 h electrophoresis (100 V) using QIAEX II Gel Extraction Kit (Quiagen). a-32 P-UMP labelled probes were synthesized using T7 RNA Polymerase (Promega). Following synthesis the probes were purified on a 5% polyacrylamid gel. Hybridization and RNA degradation were carried out using the RPA III kit (Ambion). As template for hybridization 5-20 mg total RNA was used.
Semi-quantitative PCR
As RPA consumes large quantities of RNA we did not have sufficient material to perform RPA on patients. We therefore decided to perform a semiquantitative PCR on selected CHEK2-splice variants in some of our patients. Primers were constructed specific for each splice-variant, with a corresponding wild-type specific primer-pair (Table 3 ). The lengths of the splice-variant and wild-type fragments were made similar to avoid size-influence on the relative efficiency of the PCRs (Table 4 ). The corresponding wild-type and splice-variant PCRs were carried out in the same tube, and the results were determined by incorporation of a-32 P-CTP. The program was as follows for all reactions: 941C for 5 min, followed by 30 cycles of 941C for 30 s, 501C for 30 s and 721C for 45 s, before a final step of 721C for 7 min.
Nucleotide sequence accession numbers
The nucleotide sequence for described alternative splices has been deposited under GenBank accession numbers: AY551295 (CHEK2-iso1), AY551296 (CHEK2-iso2), AY551297 (CHEK2-insX), AY551298 (CHEK2-del7), AY551299 (CHEK2-del9), AY551300 (CHEK2-del9-12), AY551301 (CHEK2-sub3), AY551302 (CHEK2-del4), AY551303
(CHEK2-del2-3), AY551304 (CHEK2-del2-12), and AY551305 (CHEK2-insZ).
Immunohistochemistry on paraffin sections
The production and characterization of mouse monoclonal antibodies DCS-270 and DCS-273 against different epitopes of human CHK2 was described . The antigen unmasking and sensitive immunoperoxidase staining protocols using the Vectastain Elite kit (Vector Laboratories) were performed as reported previously Vahteristo et al., 2002) . Nonimmune mouse immunoglobulin served as negative control. Nuclear counterstaining was omitted to allow unbiased detection of nuclear staining and photographic documentation. The results were evaluated independently by two experienced researchers, and the identity of cases compared with the mutation analysis was decoded only after evaluation of the staining patterns in a blind manner (Table 2a, 2b) .
Transfection and functional analyses
Transfection of U-2-OS cells with Myc-tagged CHK2 variants, in vitro CHK2 kinase assays using GST-p53 as substrate, estimation of protein half-life using cycloheximide, and immunofluorescence staining of Myc-CHK2 variants was performed as previously described (Falck et al., 2001a, b) . 
